Literature DB >> 16299292

Chronic Leishmania donovani infection promotes bystander CD8+-T-cell expansion and heterologous immunity.

Rosalind Polley1, Stephanie L Sanos, Sara Prickett, Ashraful Haque, Paul M Kaye.   

Abstract

It has been proposed that long-lived memory T cells generated by vaccination or infection reside within a memory compartment that has a finite size. Consequently, in a variety of acute infection models interclonal competition has been shown to lead to attrition of preexisting memory CD8+ T cells. Contrary to expectations, therefore, we found that chronic Leishmania donovani infection of Listeria-immune mice results in heightened protection against subsequent Listeria challenge. This protection was associated with bystander expansion of Listeria-specific CD8+ T cells and a bias in these cells toward a central memory T-cell phenotype with an enhanced capacity for gamma interferon production. We propose that splenomegaly, which is characteristic of visceral leishmaniasis and other tropical infections, may help promote heterologous immunity by resetting the size of the memory compartment during chronic infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299292      PMCID: PMC1307086          DOI: 10.1128/IAI.73.12.7996-8001.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  IL-15 and IL-2: a matter of life and death for T cells in vivo.

Authors:  X C Li; G Demirci; S Ferrari-Lacraz; C Groves; A Coyle; T R Malek; T B Strom
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

2.  Preferential localization of effector memory cells in nonlymphoid tissue.

Authors:  D Masopust; V Vezys; A L Marzo; L Lefrançois
Journal:  Science       Date:  2001-03-01       Impact factor: 47.728

Review 3.  Population biology of lymphocytes: the flight for survival.

Authors:  A A Freitas; B Rocha
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

4.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

5.  Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation.

Authors:  G Eberl; P Brawand; H R MacDonald
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

6.  Cutting edge: antigen-independent CD8 T cell proliferation.

Authors:  P Wong; E G Pamer
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

7.  An IFN-gamma-dependent pathway controls stimulation of memory phenotype CD8+ T cell turnover in vivo by IL-12, IL-18, and IFN-gamma.

Authors:  D F Tough; X Zhang; J Sprent
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

8.  Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens.

Authors:  G Lertmemongkolchai; G Cai; C A Hunter; G J Bancroft
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

9.  Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen.

Authors:  Rosalind Polley; Simona Stager; Sara Prickett; Asher Maroof; Soombul Zubairi; Deborah F Smith; Paul M Kaye
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

10.  Migratory properties of naive, effector, and memory CD8(+) T cells.

Authors:  W Weninger; M A Crowley; N Manjunath; U H von Andrian
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

View more
  12 in total

Review 1.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  CD8 T cell exhaustion in human visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Neetu Singh; Abhishek Kumar Singh; Madhukar Rai; David Sacks; Shyam Sundar; Susanne Nylén
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

Review 3.  Leishmaniasis: complexity at the host-pathogen interface.

Authors:  Paul Kaye; Phillip Scott
Journal:  Nat Rev Microbiol       Date:  2011-07-11       Impact factor: 60.633

Review 4.  Heterologous immunity: immunopathology, autoimmunity and protection during viral infections.

Authors:  Liisa K Selin; Myriam F Wlodarczyk; Anke R Kraft; Siwei Nie; Laurie L Kenney; Roberto Puzone; Franco Celada
Journal:  Autoimmunity       Date:  2011-01-20       Impact factor: 2.815

Review 5.  Chronic bystander infections and immunity to unrelated antigens.

Authors:  Erietta Stelekati; E John Wherry
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

6.  Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen.

Authors:  Rosalind Polley; Simona Stager; Sara Prickett; Asher Maroof; Soombul Zubairi; Deborah F Smith; Paul M Kaye
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

7.  Dendritic cells matured by inflammation induce CD86-dependent priming of naive CD8+ T cells in the absence of their cognate peptide antigen.

Authors:  Asher Maroof; Lynette Beattie; Alun Kirby; Mark Coles; Paul M Kaye
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422

8.  Immunobiology of visceral leishmaniasis.

Authors:  Rajiv Kumar; Susanne Nylén
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

9.  Engagement of NKG2D on bystander memory CD8 T cells promotes increased immunopathology following Leishmania major infection.

Authors:  Erika J Crosby; Michael H Goldschmidt; E John Wherry; Phillip Scott
Journal:  PLoS Pathog       Date:  2014-02-27       Impact factor: 6.823

Review 10.  Regulation of immunity during visceral Leishmania infection.

Authors:  Vasco Rodrigues; Anabela Cordeiro-da-Silva; Mireille Laforge; Ricardo Silvestre; Jérôme Estaquier
Journal:  Parasit Vectors       Date:  2016-03-01       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.